Viatris (VTRS)
(Delayed Data from NSDQ)
$11.39 USD
+0.01 (0.09%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $11.40 +0.01 (0.09%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.39 USD
+0.01 (0.09%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $11.40 +0.01 (0.09%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth D Momentum C VGM
Zacks News
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.99, moving -1.7% from the previous trading session.
Viatris (VTRS) Up 10.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viatris (VTRS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $10.88, marking a +0.28% move from the previous day.
Viatris (VTRS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $10.77, marking a +1.03% move from the previous day.
Viatris (VTRS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $9.96, moving +1.53% from the previous trading session.
Why is Viatris (VTRS) Stock Down 25% in the Year So Far?
by Zacks Equity Research
Viatris (VTRS) stock drops 25% in the year so far as investors do not seem to be impressed by the impending sale of its biosimilar business.
Company News for Mar 1, 2022
by Zacks Equity Research
Companies In The News Are: JLL, TGNA, XRAY, VTRS.
Viatris' (VTRS) Q4 Earnings Miss, Biocon Biologics Deal Inked
by Zacks Equity Research
Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.
Viatris (VTRS) Q4 Earnings Miss Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of -2.44% and 0.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Viatris (VTRS) Might Surprise This Earnings Season
by Zacks Equity Research
Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Theravance's (TBPH) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.
Viatris (VTRS) Stock Moves -1.58%: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $14.32, moving -1.58% from the previous trading session.
Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q4 earnings might have gained from the solid performance of Lipitor, Influvac, Viagra and EpiPen.
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
An update on the IPO of Bausch+Lomb and regular top-line and bottom-line numbers will grab investors' attention when BHC reports Q4 results.
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
AMN Healthcare (AMN) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect solid demand in some of the areas of its business.
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $15.03, moving -0.92% from the previous trading session.
Why Viatris (VTRS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $15.22, moving -0.26% from the previous trading session.
Viatris (VTRS) Gets FDA Nod for Generic Drug in Dry Eye Disease
by Zacks Equity Research
Viatris' (VTRS) subsidiary is the first to receive approval from the FDA to market a generic version of AbbVie's Restasis for the treatment of dry eye disease.
Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed at $15.30 in the latest trading session, marking a +1.53% move from the prior day.
Viatris (VTRS) Stock Moves -0.21%: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $14.59, moving -0.21% from the previous trading session.
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $14.36, marking a -1.17% move from the previous day.
Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $15.22, marking a +1.33% move from the previous day.